| abstract |
This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in the regulation of human high density lipoprotein (HDL) and pharmaceutical agents and other therapies affecting this. This invention discloses methods for the treatment and prevention of low HDL states and diseases to prevent cardiovascular diseases such as coronary heart disease (CHD), acute myocardial infarction (AMI), chronic CHD and cerebrovascular stroke and for selecting treatment in a subject and for selecting subjects for studies testing HDL elevating agents, as well as to transgenic animals. |